The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer

The approval of the first kinase inhibitor, Gleevec, ushered in a paradigm shift for oncological treatment—the use of genomic data for targeted, efficacious therapies. Since then, over 48 additional small-molecule kinase inhibitors have been approved, solidifying the case for kinases as a highly dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Essegian, Derek, Khurana, Rimpi, Stathias, Vasileios, Schürer, Stephan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659504/
https://www.ncbi.nlm.nih.gov/pubmed/33205077
http://dx.doi.org/10.1016/j.xcrm.2020.100128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7659504/
https://www.ncbi.nlm.nih.gov/pubmed/33205077
http://dx.doi.org/10.1016/j.xcrm.2020.100128

Ejemplares similares